22.3 C
Los Angeles
Sunday, July 21, 2024

Kona International Airport in Hawaii to Reopen After Temporary Closure Due to Runway Cracks

Overview Ellison Onizuka Kona International Airport at Keahole...

Unraveling the Controversy: Iran’s Nuclear Program and the Call for Weapons

Introduction In recent times, Iran's nuclear program has...

Gossamer Bio to Host Webcast: Will Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

BusinessGossamer Bio to Host Webcast: Will Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

SAN DIEGO, December 13, 2023–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq: GOSS)

Gossamer Bio to Host Webcast : A clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH).

Today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients.

Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.

The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company’s website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following:

Date / Time: December 18, 8:30 am EST
Dial-in Number: 1-800-285-6670
Conference Reference: Gossamer Bio – Torrey OLE Update
Live Webcast: https://edge.media-server.com/mmc/p/pqeu4vsm

A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company’s website, www.gossamerbio.com.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

See Also :

Check out our other content

Check out other tags:

Most Popular Articles